Lasa Supergenerics Complete Financial Statements

In FYNone, Lasa Supergenerics (LASA) reported revenue ₹107 Cr, net profit ₹-36 Cr and EPS ₹-7.20, with a net profit margin of -13.4% and ROE of -22.6%. Full financial statements from FY2016 to FY2025 (10 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Lasa Supergenerics share price chart.

10 Years of Data
2025 - 2016

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -13.38% 2025 data
EBITDA Margin -6.34% 2025 data
Operating Margin -7.00% 2025 data
Return on Assets -18.63% 2025 data
Return on Equity -22.62% 2025 data

Balance Sheet Ratios

Current Ratio 33.00 2025 data
Debt to Equity 1.21 2025 data
Equity Ratio 82.35% 2025 data
Asset Turnover 1.39 2025 data

LASA Revenue, Net Profit & EBITDA — Year-on-Year Growth

LASA YoY (March 2025 vs Period) — revenue -24.6%, net profit -89.5%, EBITDA -277.8%, expenses -7.2%.

Revenue Growth
-24.6%
Year-over-Year
Net Profit Growth
-89.5%
Year-over-Year
EBITDA Growth
-277.8%
Year-over-Year
Expense Growth
-7.2%
Year-over-Year
Assets Growth
-32.5%
Year-over-Year
Equity Growth
-13.4%
Year-over-Year
Liabilities Growth
-32.5%
Year-over-Year
Operating Cash Flow Growth
+111.8%
Year-over-Year
Investing Cash Flow Growth
-100.0%
Year-over-Year
Financing Cash Flow Growth
+50.0%
Year-over-Year

LASA Income Statement — Revenue, EBITDA & Net Profit

Lasa Supergenerics revenue ₹107 Cr, EBITDA ₹-34 Cr, net profit ₹-36 Cr, EPS ₹-7.20 (None) — net profit margin -13.4%. Explore LASA intrinsic value to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016
Revenue 107 142 104 131 137 202 168 170 247 201 0
Expenses 141 152 102 136 121 155 137 159 202 153 0
EBITDA -34 -9 2 -5 16 47 30 12 45 48 0
Operating Profit Margin % -72.00% -7.00% 2.00% -5.00% 12.00% 23.00% 18.00% 7.00% 17.00% 23.00% 0.00%
Depreciation 10 12 11 13 15 16 17 19 18 8 0
Interest 1 3 2 4 0 2 8 8 11 12 0
Profit Before Tax -44 -19 -19 -42 -6 30 5 -16 15 2 0
Tax 0 0 3 -4 -1 7 1 -4 3 0 0
Net Profit -36 -19 -22 -39 -5 23 4 -12 12 2 0
Earnings Per Share (₹) -7.20 -2.95 -4.34 -7.71 -1.06 5.60 0.89 -5.26 5.43 1.15 0.00

LASA Balance Sheet — Assets, Liabilities & Shareholders' Equity

LASA total assets ₹102 Cr, total equity ₹84 Cr, total liabilities ₹102 Cr (2025) — ROE -22.6%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
ASSETS
Total Assets 102 151 164 209 208 232 259 287 228 0
Current Assets 33 38 39 66 64 76 86 109 79 0
Fixed Assets 68 110 119 137 143 152 162 170 119 0
Capital Work in Progress 0 3 5 5 0 0 7 7 30 0
Investments 25 0 0 0 0 0 0 0 0 0
Other Assets 0 39 40 67 65 80 90 110 80 0
LIABILITIES
Total Liabilities 102 151 164 209 208 232 259 287 228 0
Current Liabilities 1 5 3 7 8 15 46 62 83 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 84 97 118 158 159 142 105 117 76 0
Share Capital 50 50 50 50 41 41 23 23 0 0
Reserves & Surplus 34 47 68 108 118 101 82 95 75 0

LASA Cash Flow Statement — Operating, Investing & Financing

Lasa Supergenerics operating cash flow ₹2 Cr, investing ₹0 Cr, financing ₹-2 Cr, net cash flow ₹0 Cr (2024).

Periods ₹ Crores
Particulars March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016
Operating Activities 2 -17 9 41 14 41 40 -3 0
Investing Activities 0 11 -3 -4 -2 -7 -44 0 0
Financing Activities -2 -4 0 -36 -10 -33 4 0 0
Net Cash Flow 0 -10 6 1 2 0 0 -3 0